08/15/22 7:30 AMNasdaq : GRNA earningsGreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company ProgressGreenLight raised $108.4 million in private placement led by S2G Ventures with strong participation from existing and new investors with cash expected to fund critical programs through the first half of 2023. GreenLight and Samsung Biologics completed their first commercial-scale engineering runRHEA-AIpositive
08/12/22 7:21 AMNasdaq : GRNA GreenLight Biosciences announces $109 million financingGreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announcedRHEA-AIpositive
08/01/22 9:00 AMNasdaq : GRNA covid-19GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccineGreenLight’s messenger RNA production process is transferable to large-scale equipment and CMO facilities Technology transfer and scale-up from lab bench to Samsung’s commercial facility was completed in seven months GreenLight’s mRNA synthesis reaction had a titer of 12g/L at a commercial scaleRHEA-AIvery positive
07/29/22 4:40 PMNasdaq : GRNA covid-19NIH, GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variantsGreenLight Biosciences has announced a collaboration with the National Institutes of Health (NIH) to develop COVID-19 vaccines that are more broadly protective against new variants and with longer-lasting effects. “This is a tremendous opportunity for usRHEA-AIneutral
05/10/22 1:04 PMNasdaq : GRNA GreenLight’s honeybee-saving RNA solution named finalist in World Changing Ideas AwardAn RNA-based solution by GreenLight Biosciences designed to protect honeybees from the Varroa destructor mite was named a finalist by Fast Company for its 2022 World Changing Ideas Awards. This is the first RNA-based solution that directly targets theRHEA-AIneutral
03/29/22 1:04 PMNasdaq : GRNA managementcovid-19Co-developer of COVID-19 Vaccine Joins GreenLight Advisory BoardGreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant health, is proud to welcome Barney Graham, MD, PhD., to its Human Health Scientific Advisory Board.RHEA-AIvery positive
03/14/22 8:55 AMNasdaq : GRNA GreenLight Biosciences Holdings, PBC (GRNA) enters into multitarget licensing agreement with Serum Institute of India to develop and commercialize messenger RNA products for emerging markets globallySerum Institute of India has engaged GreenLight to design three messenger RNA products, including a vaccine for shingles. Serum Institute of India also has an option to expand the relationship further for two additional vaccine or therapeutic targets. Serum Institute of India will receive a licenseRHEA-AIvery positive
02/07/22 1:27 PMNasdaq : GRNA GreenLight agrees to field station in Spain to boost research and development for key plant health projectsGreenLight Biosciences, a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, today announced its agreement to operate a field research station in Spain. Located south of Seville, a keyRHEA-AIneutral